US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
VC

VCEL

Stock Vericel Corp
$38.34

Nasdaq Global Market · Healthcare · US

Sharia status
COMPLIANT
Per our secondary compliance provider · assessed 2026-08-06
HTR non-permissible income 2.54%

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.
Trade setup SEPARATE FROM SHARIAH
🔴 AVOID
The main driver: lagging the market by 13.8%. Too many signals pointing the wrong way. Wait for the picture to...
41
of 100
Setup confidence — system conviction, not win probabilityD
Why this signal?
Structure2 of 5 timeframes bullish · 87.0% aligned
VWAPPrice below VWAP ($38.81)
VolumeRelative volume 3.2× the 20-day average
Momentum10-day rate of change -8.5%
Overall readAVOID

Vericel Corp (VCEL) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-06). See the full ratio breakdown and business-activity screen below for the reasoning.

Market & analysts
Price target
$60.57
+58.0% · 7 analysts
Institutional own.
111.0% *
of shares
Momentum (10d)
-8.5%
rate of change
SMC grade
D · 41
87.0% aligned
COMPLIANT
Sharia compliance
2.54%
Non-permissible income — HTR, from filings (2025-12-31)
D · 41
SMC grade — 87.0% timeframe alignment
-8.5%
Rate of change (10d)
$60.57
Price target (+58.0%) · 7 analysts
111.0%
Institutional ownership *

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for VCEL — this runs off the critical path so the page paints first. It will appear here on its own.

Tracked investors holding VCEL
InvestorFirmPositionWeightAs of
Ken Fisher Fisher Asset Management $8M 0.0% 2026-06-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

48.3143.5738.8334.0829.342025-09-122026-03-132026-09-11

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
36.27
S2
36.97
S1
37.42
PIVOT
38.12
R1
38.57
R2
39.27
R3
39.72

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

7-day expected range
36.89 44.89
±9.77% from 40.89, made 2026-09-03 · resolves 2026-09-10
STRONG SELL
from 19 indicators
Not enough resolved predictions yet — 0 of 10 needed before we publish an accuracy figure. 22586 forecast(s) are currently open and will be scored automatically when their horizon expires.

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

Technical Summary

STRONG SELL
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG SELL
1 buy · 0 neutral · 11 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)31.20NEUTRAL
Stochastic %K (14)16.53BUY
CCI (20)-128.66BUY
Williams %R (14)-83.47BUY
MACD (12,26,9)-0.31SELL
ROC (10)-6.90SELL
Momentum (10)-2.84SELL
EMA (10)39.70SELL
SMA (10)39.72SELL
EMA (20)40.99SELL
SMA (20)41.34SELL
EMA (30)41.73SELL
SMA (30)42.60SELL
EMA (50)42.02SELL
SMA (50)44.17SELL
EMA (100)40.86SELL
SMA (100)40.40SELL
EMA (200)38.99SELL
SMA (200)38.15BUY

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

About Vericel Corp

Healthcare · Biotechnology

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

vcel.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Verdict

🔴 AVOID

The main driver: lagging the market by 13.8%. Too many signals pointing the wrong way. Wait for the picture to improve before committing capital.

Scores: 1 bullish / 3 bearish

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

TimeframeBiasBars
📅 Daily BEARISH 62
⏰ 4H BEARISH 36
🕐 1H BEARISH 98
⏱ 15-Min BULLISH 130
⏲ 5-Min BULLISH 234

Momentum & Volume

-1.57
MACD (no fresh cross)

Peer Movement

Peer movement computing — it will appear here on its own.

Insider Activity (90d)

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

NEUTRAL   report date 2026-09-08 · Asset managers net 912361 (-21819)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.